Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| NSI-189 | Phenibut | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 40 mg once daily (for educational context — investigational compound, not approved for any indication) | 250-750 mg as needed, maximum 1-2 times per week (for educational context — carries significant dependence risk) |
| Timing | Once daily, time of day not definitively established from clinical data. With or without food. | On an empty stomach (food significantly reduces absorption). Onset 2-4 hours. Effects last 4-8 hours with residual effects up to 24 hours. Half-life approximately 5.3 hours. |
| Cycle Duration | Phase 2 trial used 12-week treatment duration. Long-term safety data unavailable. | STRICTLY intermittent use only — maximum 1-2 times per week. NEVER use daily for more than 1 week. Tolerance develops within days, leading to dose escalation and dependence. |
| Evidence Level | moderate_human | moderate_human |
Benzylpiperizine-aminopyridine compound that stimulates neurogenesis of human hippocampus-derived neural stem cells in vitro and increases hippocampal volume in vivo. Mechanism is independent of serotonin or norepinephrine reuptake inhibition — fundamentally distinct from traditional antidepressants. Activates the TrkB receptor (BDNF receptor) and downstream Akt/PI3K signaling pathways to promote synaptic plasticity, long-term potentiation, and neuronal survival. Enhances BDNF expression in hippocampal subregions critical for memory consolidation and mood regulation. Originally developed as ALTO-100 (Alto Neuroscience) for treatment-resistant depression with cognitive impairment.
40 mg once daily (for educational context — investigational compound, not approved for any indication)
Once daily, time of day not definitively established from clinical data. With or without food.
Phase 2 trial used 12-week treatment duration. Long-term safety data unavailable.
Beta-phenyl derivative of GABA that crosses the blood-brain barrier (unlike GABA itself) due to the addition of a phenyl ring. Acts as a full agonist at GABA-B receptors with 30-68x lower affinity than baclofen, requiring correspondingly higher doses. Also binds to and blocks alpha-2-delta subunit-containing voltage-dependent calcium channels (VDCCs), making it a gabapentinoid similar to gabapentin and pregabalin. At low concentrations, mildly increases dopamine levels in the brain, providing stimulatory and nootropic effects alongside anxiolysis. Weak agonist activity at GABA-A receptors at higher doses.
250-750 mg as needed, maximum 1-2 times per week (for educational context — carries significant dependence risk)
On an empty stomach (food significantly reduces absorption). Onset 2-4 hours. Effects last 4-8 hours with residual effects up to 24 hours. Half-life approximately 5.3 hours.
STRICTLY intermittent use only — maximum 1-2 times per week. NEVER use daily for more than 1 week. Tolerance develops within days, leading to dose escalation and dependence.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →